Business Context and Reporting Period
This Form 8-K was filed by Aeglea Biotherapeutics, Inc. (not Spyre Therapeutics, Inc.) on November 30, 2022, reporting events occurring on November 28, 2022. The filing addresses Item 5.02 regarding the appointment of a new Chief Executive Officer and the resignation of the Interim CEO.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and personnel changes.
Material Changes
- Leadership Transition: Jeffrey M. Goldberg was appointed President and Chief Executive Officer, effective November 29, 2022. He also joined the Board as a Class III director.
- Resignation: Jim Kastenmayer resigned as Interim CEO but will remain as General Counsel and Corporate Secretary.
- Compensation Package: Mr. Goldberg's annual base salary is set at $600,000, with a cash bonus eligible up to 50% of base salary and a $35,000 annual housing allowance.
- Equity Grant: Mr. Goldberg received an option to purchase 1,884,838 shares of common stock. Vesting occurs over four years (25% after one year, then monthly).
Guidance, Risks, and Contingencies
The filing details significant severance contingencies for Mr. Goldberg:
- Standard Termination: If terminated without cause or for good reason, he receives 12 months of base salary, 100% of the target bonus, 12 months of COBRA premiums, and accelerated vesting of equity awards (as if 12 additional months of service occurred).
- Change in Control: If terminated within 12 months of a change in control (or 3 months prior), he receives 12 months of base salary, 100% of the target bonus, 12 months of COBRA premiums, and 100% vesting of all outstanding equity awards.
Investor Verification Checklist
- Verify the exact closing sale price of Aeglea stock on November 29, 2022, to determine the exercise price of the 1,884,838 stock options granted.
- Review the full offer letter and severance agreement to be filed in the 2022 Form 10-K for detailed performance criteria regarding the cash bonus.
- Confirm the impact of the new CEO's appointment on the company's strategic direction and pipeline development, as this filing contains no operational updates.
- Monitor future filings for any changes to the Board composition resulting from Mr. Goldberg's appointment as a Class III director.